NEW INHIBITORS AGAINST accD3 GENE OF MYCOBACTERIUM TUBERCULOSIS, IN-SILICO STUDY AND IN -VITRO APPLICATION

Mycobacterium tuberculosis (Mtb) is a pathogenic bacteria species in the genus Mycobacterium and the causative agent of most cases of tuberculosis. Tuberculosis (TB) is the leading cause of death in the world from a bacterial infectious disease. This antibiotic resistance strain lead to development of the new antibiotics or drug molecules which can kill or suppress the growth of Mycobacterium tuberculosis. The aim of  this study  is  discovery  a  new  drug molecules against  the  product of  accD3 gene which play a vital role in mycolic  acid  biosynthesis  pathway (MAP). As a first step  accD3  gene amplified  from the  complete genome of  Mycobacterium  tuberculosis Iraqi isolates and sequenced, eight  out of  twenty of  the  resulted  sequences were chosen to achieve the in silico studies, these  sequences  have  deposited in GenBank database with strain  names (ALQM1,  ALQM2,  ALQM3, ALQM4, ALQM5, ALQM6, ALQM7,  ALQM8 ) and  Accession  numbers  (LC006979, LC008196, LC009412, LC009414,  LC034168,  LC038020,  LC041163,  LC041368) respectively, two drug molecules  resulted from in silico studies and  used in the practical  application  to  prove  the  in vitro inhibitory  ability  of  these  molecules on  viable cells  of  M. tuberculosis, REMA which is a colorimetric assay was used in this research to estimate the inhibitory application of these molecules.